Evidence signal01
Semax had more than a purely mechanistic record
FDA reviewed human references involving the nominated neurological conditions, including intranasal administration.
FDA briefing pp. 22–28Day 2 recordPCAC favorable
Peptide dossier / July 23–24, 2026Semax
Foreign-use history and pharmacology outweighed a weak direct clinical record for the panel.
Semax had a wider pharmacology literature and limited clinical references, but FDA found the direct clinical record too small and methodologically weak for the nominated uses.
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Editorial review
Analysis
FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.
Decisive limitation02
The direct clinical evidence remained weak
The available studies were few, small and insufficiently controlled or reported; nonclinical volume did not solve the clinical-evidence gap.
FDA briefing pp. 25–28, 42–43PeptideBase read
The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
The case made in the room
Testimony
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
5published speaker moments
Only named speaker moments reconciled against a word-timestamped machine transcript of the official recording appear here. The method is two-pass transcript reconciliation: both passes read that same transcript, so this is not audio review and not independent primary-source confirmation. Where the two passes disagreed about who was speaking, the moment was withheld rather than published. Statements remain attributed arguments unless the underlying evidence was independently established from a named source outside the hearing record, and each moment carries its own disclosed limitations.
01Supports listing
Alex Tatem, MD
Board-certified urologist, private practice, Indianapolis
Verify credentialsAttributed testimony
The foreign-use and stroke-literature case
Tatem cited Russian regulatory approval dating to 1994 and a 110-patient stroke cohort reporting BDNF and Barthel-index outcomes. Those foreign sources and their methodological quality were not resolved within this hearing record.
What is not established
- One identity cue only — self-introduction, no independent moderator naming located. The moderator says only "Thank you", with no name.
- Automatic speech recognition renders the surname 'Tatum' throughout; the site displays the correct spelling, 'Tatem'. This is a transcription artefact, not an unresolved identity — the speaker is independently identified at the linked practice profile.
- No urology-specific statement is made in this session. The credential shown comes from the linked independent practice profile, not from this session.
Semax session public comment · attributed argument, not an established factTranscript-reconciled — second review passedPlay the source06:28:36–06:32:42
02Supports listing
Ricardo Rosselló, PhD
Biomedical scientist and former Governor of Puerto Rico
Verify credentialsAttributed testimony
The access argument
Rosselló argued that removing supervised clinical access without a replacement redirects patients toward an unregulated market, and asked for a framework that restores supervised access alongside quality standards.
“I respectfully ask the committee to add C-Max to the 503A bulk list”
What is not established
- The transcript renders Semax as "C-Max"/"CMAX" throughout; the quote preserves the transcript’s wording.
Semax session public comment · policy and access argumentTranscript-reconciled — second review passedPlay the source06:36:32–06:40:24
03Regulated-access context · not substance-specific
Ben Gonzalez, MD
Solo practising physician; Medical Director, Atlantis Medical Wellness Center; CMO, Apex MD
Verify credentialsAttributed testimony
The online-market safety warning
Gonzalez relayed an account of a patient who believed he had experienced a seizure after injecting a peptide bought online, and argued for physician and patient choice under supervised care. The account is not specific to Semax and does not establish causation.
Semax session · anecdote not specific to SemaxTranscript-reconciled — second review passed; stance basis citedPlay the source06:45:02–06:48:40
Attributed testimony
The framework-mismatch objection
Hertig argued that Semax cannot be reconciled with the Section 503A framework and that the evidence does not support safety or effectiveness, citing 21 CFR 216.23.
“I would again strongly recommend that you do not add this product to the 503a bulks list”
What is not established
- Automatic speech recognition renders the surname inconsistently across sessions, with a differing consonant in half. The spelling shown here is confirmed independently of the transcript by Wired's coverage of this hearing, which names him and his organisation. The variation is a transcription artefact, not an unresolved identity.
- The moderator’s naming is garbled to "Dr. Hating" — a genuine second utterance, not a clean name match.
Semax session public comment · attributed argument, not an established factTranscript-reconciled — second review passedPlay the source06:18:25–06:20:33
05Opposes listing
Peter Lurie, MD, MPH
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsAttributed testimony
The hearing-wide case against all seven
Lurie said CSPI opposed adding all seven substances, for three reasons: that listing would be inconsistent with FDA’s own compounding standards, that compounded products pose distinct consumer risks, and that listing would remove incentives to develop products through the standard drug-approval pathway.
What is not established
- Identity rests on a self-introduction plus the chair’s sequential numbering ("speaker number three"), not on the chair speaking his name.
BPC-157 session public comment, speaker #3 · explicitly applied to all seven substancesTranscript-reconciled — second review passedPlay the source00:57:02–00:59:43
Foreign-use history and stroke literature make Semax a meaningful candidate for supervised access.
Foreign-use history and unresolved literatureWhat supports it
The hearing described Russian use and clinical literature. The underlying sources, methods and correspondence to the exact nominated forms, routes and uses were not fully resolved in the reviewed record.
FDA’s answer
FDA found insufficient evidence supporting effectiveness for the nominated uses and insufficient clinical information to characterize safety.
FDA Day 2 presentation · 07:09:13PeptideBase assessment
Foreign-use history may justify closer source review. Without matched, source-resolved evidence, it cannot carry the effectiveness or safety conclusion.
Why the judgments diverged
Foreign-use history and harm reduction met a route-matched evidence test.
The favorable majority appears to have given weight to foreign-use history, neurobiological rationale and the argument for supervised access. FDA required evidence tied to the exact nominated forms, routes and uses and found it insufficient.
Editorial inference from the hearing record—not an attributed rationale for every voterClaim versus record
Claim checks
These are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
Recurring claim
A large pharmacology literature establishes clinical effectiveness.
Official record
FDA said only two available clinical references informed the effectiveness review for the nominated uses and that they lacked sufficient study-design detail.
What it does not establish
FDA briefing pp. 22–28, 42–43A large nonclinical literature does not replace controlled evidence for the exact chemical form, route and clinical use.
Recurring claim
The migraine and trigeminal-neuralgia studies showed reliable analgesic benefit.
Official record
FDA described the relevant studies as small, uncontrolled and open-label; it said Semax did not resolve pain for the majority of subjects in those analyses.
What it does not establish
FDA briefing pp. 25–28The studies’ small samples, missing controls, unclear scales and incomplete endpoint reporting prevent confident effectiveness conclusions.
Evidence architecture
Evidence
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | limited | FDA-record summaryFDA relied on two clinical references with limited study-design detail. | LocatorBriefing pp. 22–28, 42–43 |
| Nonclinical evidence | indirect | FDA-record summaryA substantial pharmacology literature existed, but it did not establish clinical effectiveness for the nominated uses. | LocatorBriefing pp. 28–36 |
| Exact-form match | unresolved | FDA-record summaryFDA reported that “it is often unclear whether the semax discussed in the sources considered for this section is the salt formulation or the free base.” The record does not establish which form the evidence concerns. | LocatorBriefing pp. 6–17 |
| Nominated-route match | limited | FDA-record summarySome intranasal evidence aligned with one proposed route; the record did not establish the full intranasal/SC product set. | LocatorBriefing pp. 6, 22–28 |
| Evaluated-use match | limited | FDA-record summarySmall studies addressed the nominated conditions but were methodologically inadequate or showed limited effect. | LocatorBriefing pp. 22–28 |
| Product characterization | not well characterized | FDA-record summaryFDA concluded that “semax (free base) is considered to be not well-characterized from the physical and chemical characterization perspective”; the same conclusion is stated for semax acetate. | LocatorBriefing pp. 7–18 |
| Human safety | limited | FDA-record summaryFDA found insufficient clinical information to characterize safety and immunogenicity. | LocatorBriefing pp. 36–43 |
| Historical compounding use | limited | FDA-record summaryFDA found the extent of historical use in compounding unclear. | LocatorBriefing pp. 18–22 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
FDA findings
Five parts of the staff case.
01characterizationBoth Semax free base and Semax acetate were considered not well characterized.Day 2 pp. 116, 119
07:00:0102effectivenessFDA found insufficient evidence supporting effectiveness for the nominated uses.Day 2 pp. 126–131
07:09:1303safetyFDA found insufficient clinical information to characterize safety and raised potential immunogenicity concerns.Day 2 pp. 132–139
07:20:4404historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 140–144
07:24:0405recommendationFDA proposed that neither Semax free base nor Semax acetate be included on the 503A Bulks List.Day 2 pp. 144–145
07:25:40
07:00:0102effectivenessFDA found insufficient evidence supporting effectiveness for the nominated uses.Day 2 pp. 126–131
07:09:1303safetyFDA found insufficient clinical information to characterize safety and raised potential immunogenicity concerns.Day 2 pp. 132–139
07:20:4404historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 140–144
07:24:0405recommendationFDA proposed that neither Semax free base nor Semax acetate be included on the 503A Bulks List.Day 2 pp. 144–145
07:25:40
What changes the assessment
Sources
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
01
Controlled trials of the exact form, route and nominated neurological uses
02
Clinical safety, immunogenicity and pharmacokinetic evidence
03
Validated identity, impurity and finished-product specifications
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Continue the record
View all sevenRelated peptide dossiers
Day 2
Epitalon
The official record contained circadian and melatonin-related findings, but no direct insomnia trial using the nominated SC product and no clinical safety record.
Open dossierDay 2Emideltide (DSIP)
Emideltide had older human studies, but the record was small, methodologically uneven and largely intravenous rather than the nominated subcutaneous route.
Open dossier